PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase I drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PYX-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PYX-201 overview
PYX-201 is under development for the treatment of non-small cell lung cancer, triple-negative breast cancer, solid tumors, metastatic breast cancer, head and neck cancer squamous cell carcinoma, pancreatic ductal adenocarcinoma, ovarian cancer, hepatocellular carcinoma, soft tissue sarcoma and kidney cancer (renal cell cancer),human epidermal growth factor receptor 2 positive and negative breast cancer and thyroid cancer. The drug candidate is a monoclonal antibody conjugate which carries four auristatin (AUR0101), microtubule depolymerizing inhibiting payloads and acts by targeting oncofetal fibronectin. It is being developed based on Flexible Antibody Conjugation Technology (FACT). It is administered by intravenous route.
Pyxis Oncology overview
Pyxis Oncology is an immuno-oncology company that develops antibody drug conjugates (ADC) and immunotherapies for cancer. The company’s pipeline products include PYX-201, PYX-106 and PYX-107. Its PYX-201, is an antibody-drug conjugate, which treats solid tumors; PYX-106, human monoclonal antibody, treats solid tumors and PYX-107 for melanoma and liposarcoma. The company utilizes its proprietary flexible antibody conjugation technology (FACT) platform to develop ADCs. Pyxis Oncology’s platform technology analyses promising tumor targets and acquire highly specific antibodies to these tumor targets. Pyxis Oncology is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of PYX-201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
